Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Absorption differs slightly between sites
Many women notice these sleep changes during perimenopause
Taking NR activates sirtuins by increasing NAD+ levels
Dose Escalation GLP-1 medications are typically introduced at a low dose and increased gradually
Patients typically begin with a lower dose and gradually increase over several weeks based on tolerance and weight loss response
Quick Specs Form: Lyophilized powder (white to off-white) Purity: 99% by HPLC every batch Identity: MS molecular-weight confirmed every batch CAS Number: 2381089-83-2 Also Known As: LY3437943, triple incretin agonist Sequence Length: 39 amino acids Molecular Formula: C228H350N48O66 (confirm per COA) Molecular Weight: ~4731 Da (confirm per COA) Receptor Targets: GIPR + GLP-1R + GCGR Modification: Fatty-diacid side chain (albumin binding) Half-Life: ~6 days (research literature) Peptide Type: Synthetic triple incretin receptor agonist COA: Janoshik third-party publicly verifiable Manufacture: Lyophilized & QC-released in-house Storage: 20C sealed | 28C reconstituted Shelf Life: 24 months unopened (lyophilized) Certificate of Analysis Janoshik ThirdParty Verification Every batch is independently tested by Janoshik
US$ 29.00
US$ 27.85
US$ 23.72
US$ 25.46
US$ 22.80
